2019 American Transplant Congress
Large Series Of Liver Transplantation In Patients With Portal Vein Thrombosis
Lahey Hospital & Medical Center, Burlington, MA
*Purpose: Portal vein thrombosis (PVT) is common in the cirrhotic population and no longer considered an absolute contraindication to liver transplantation in most centers.*Methods: Retrospective…2019 American Transplant Congress
CXCL12-CXCR4-Mediated Chemotaxis is a Potential Mechanism for Monocyte Recruitment in Ischemia-Reperfusion Injury in Orthotopic Liver Transplant Patients
*Purpose: Ischemia-reperfusion injury (IRI) elicits cellular damage which lowers allograft survival in orthotopic liver transplant (OLT) patients. Damage-associated molecular patterns, such as high-mobility group box…2019 American Transplant Congress
Outcomes of Portal Vein Extension Grafts in Pancreas Transplantation: A Single-Centre Analysis
*Purpose: Surgical dogma suggests that portal vein extension grafts (PVEGs) in pancreas transplantation should be strenuously avoided, though the evidence-base is lacking. In our unit,…2019 American Transplant Congress
Portal Vein Thrombosis Discovered at Liver Transplant: Barrier to Success
*Purpose: Portal vein thrombosis (PVT) present at listing or diagnosed while listed enables potential treatment pre-liver transplant (OLT). Main PVT at OLT (mPVT) complicates surgeries…2019 American Transplant Congress
Anticoagulation in Post-Liver Transplant Recipients with Portal Vein Thrombosis
*Purpose: The purpose of this study is to compare safety and efficacy outcomes in liver transplant recipients with portal vein thrombosis (PVT) at the time…2018 American Transplant Congress
Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for the Treatment of Medically Refractory Hepatic Encephalopathy (HE) in Patients with ESLD and Significant Portal-Venous Shunting
Liver and Pancreas Transplantation, Dumont-UCLA Liver Transplant Center, Los Angeles, CA.
Background: Patients with medical refractory HE represent a challenging group of patients. Plagued by repeated hospitalizations, long lengths of stay (LOS) and high healthcare costs,…2018 American Transplant Congress
Sufficient Hepatic Artery Flow Redeems Poor Portal Vein Flow after Liver Transplantation in Patients with Porta Vein Thrombosis
General Surgery, Cleveland Clinic, Cleveland, OH.
Objective:Although portal vein thrombosis(PVT) in liver transplantation is no longer a contraindication, it remains technically challenging. Insufficient intraoperative PV flow after PV thrombectomy/reconstruction was reported…2018 American Transplant Congress
Portal Vein Thrombosis (PVT) in Liver Transplantation – Recent Experience
Ochsner Multi-Organ Transplant Institute, Ochsner Medical Center, New Orleans, LA.
From 01-Nov-2012 to 31-Oct-2017, 1025 liver transplants were done at our center. Excluding retransplants and combined liver-kidney transplants, 830 transplants were studied for this abstract…2018 American Transplant Congress
Liver Transplantation in Patients with Spontaneous Spleno-Renal Shunt
Aim: Our aim was to describe the outcomes of liver transplantation (LT) in patients with spontaneous spleno-renal shunt (SSRS) and to define the adequate portal…2018 American Transplant Congress
Intervention for Splenorenal Shunt May Decrease the Incidence of Post-Liver Transplant Acute Kidney Injury
Dept. of Surgery, University of Virginia Health System, Charlottesville, VA.
Background: Splenorenal shunt (SRS) is a type of portosystemic shunt that develops frequently in the setting of chronic portal hypertension and cirrhosis. It remains controversial…
American Transplant Congress abstracts